Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-15512 (Tryptyr) for Dry Eye Disease (COMET-2)
NCT05285644Phase 3Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acoltremon in dry eye disease (DED), sponsored by Aerie Pharmaceuticals. Started May 2022; status: completed.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05285644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285644.